These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 37002907

  • 1. Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera.
    Krecak I, Skelin M, Verstovsek S.
    Expert Rev Hematol; 2023 May; 16(5):305-316. PubMed ID: 37002907
    [Abstract] [Full Text] [Related]

  • 2. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
    Illés Á, Pinczés LI, Egyed M.
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
    [Abstract] [Full Text] [Related]

  • 3. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
    Wagner SM, Melchardt T, Greil R.
    Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
    [Abstract] [Full Text] [Related]

  • 4. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
    Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ, PROUD-PV Study Group.
    Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
    [Abstract] [Full Text] [Related]

  • 5. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
    Jin J, Qin A, Zhang L, Shen W, Wang W, Zhang J, Li Y, Wu D, Xiao Z.
    Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera.
    Gerds AT, Castro C, Snopek F, Flynn MM, Ellis AG, Manning M, Urbanski R.
    J Comp Eff Res; 2023 Sep; 12(9):e230066. PubMed ID: 37531245
    [Abstract] [Full Text] [Related]

  • 7. [Treatment strategies for low-risk polycythemia vera].
    Ota S.
    Rinsho Ketsueki; 2024 Sep; 65(8):810-818. PubMed ID: 39231712
    [Abstract] [Full Text] [Related]

  • 8. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.
    Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, Masciulli A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A.
    NEJM Evid; 2023 Jun; 2(6):EVIDoa2200335. PubMed ID: 38320126
    [Abstract] [Full Text] [Related]

  • 9. Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b.
    Qin A, Wu D, Liao J, Xie S, Chen H, Gao Y, Cui J, Su X, Miyachi N, Sato T, Li Y, Zhang J, Shen W, Wang W.
    Front Pharmacol; 2024 Jun; 15():1455979. PubMed ID: 39386026
    [Abstract] [Full Text] [Related]

  • 10. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
    Barbui T, Carobbio A, De Stefano V, Alvarez-Larran A, Ghirardi A, Carioli G, Fenili F, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Calabresi L, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Ramundo F, Lunghi F, Scaffidi L, Bucelli C, Cattaneo D, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A, Vannucchi AM.
    Ann Hematol; 2024 Feb; 103(2):437-442. PubMed ID: 38060001
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.
    Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, VanWart SA, Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Kirito K.
    Int J Hematol; 2022 Aug; 116(2):215-227. PubMed ID: 35430707
    [Abstract] [Full Text] [Related]

  • 12. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
    Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C.
    Ann Hematol; 2024 Jul; 103(7):2299-2310. PubMed ID: 38438627
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.
    Shimoda K, Qin A, Komatsu N, Kirito K.
    Int J Hematol; 2024 Aug; 120(2):151-156. PubMed ID: 38951434
    [Abstract] [Full Text] [Related]

  • 14. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
    Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A.
    Lancet Haematol; 2021 Mar; 8(3):e175-e184. PubMed ID: 33476571
    [Abstract] [Full Text] [Related]

  • 15. Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms.
    Huang CE, Wu YY, Hsu CC, Chen YJ, Tsou HY, Li CP, Lai YH, Lu CH, Chen PT, Chen CC.
    J Formos Med Assoc; 2021 Feb; 120(2):863-873. PubMed ID: 32873465
    [Abstract] [Full Text] [Related]

  • 16. [Ropeginterferon alfa-2 b for the therapy of polycythemia vera].
    Červinek L.
    Vnitr Lek; 2020 Feb; 66(5):309-313. PubMed ID: 32942868
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.